CIMETIDINE - AN INHIBITOR AND AN INDUCER OF RAT-LIVER MICROSOMAL CYTOCHROME-P-450

被引:11
作者
WRIGHT, AWE [1 ]
WINZOR, DJ [1 ]
REILLY, PEB [1 ]
机构
[1] UNIV QUEENSLAND,DEPT BIOCHEM,ST LUCIA,QLD 4072,AUSTRALIA
基金
英国医学研究理事会;
关键词
D O I
10.3109/00498259109039461
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Cimetidine pretreatment of male Sprague-Dawley rats caused a significant increase in the specific content of total hepatic cytochrome P-450, supporting the hypothesis that this H2-receptor antagonist has monooxygenase induction effects. 2. Quantitative ultrastructural studies of liver of cimetidine-pretreate animals also supported this hypothesis in showing a significant proliferation of smooth endoplasmic reticulum. These ultrastructural changes were qualitatively similar to those produced by treatment of rats with phenobarbital, a well-characterized monooxygenase-inducing agent whose effect were studied for comparative purposes. 3. Competitive inhibition of metoprolol alpha-hydroxylation by cimetidine in liver microsomes prepared from untreated animals (K(i) = 18.8-mu-M) was also demonstrated. 4. These results allowed testing of the hypothesis (Burnet et al. 1986) that inhibition of a defined monooxygenase should lead to induction of the synthesis of the relevant cytochrome P-450 isozyme. 5. The finding that metoprolol alpha-hydroxylase activity of liver microsomes was lowered, not elevated, by pretreatment of animals with cimetidine argues against the concept of a causal link between monooxygenase inhibition and induction.
引用
收藏
页码:193 / 203
页数:11
相关论文
共 38 条
[1]  
ADEDOYIN A, 1987, DRUG METAB DISPOS, V15, P127
[2]   DOSE-DEPENDENT EFFECT OF CIMETIDINE ON PHENYTOIN KINETICS [J].
BARTLE, WR ;
WALKER, SE ;
SHAPERO, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (05) :649-655
[3]  
BURNET F, 1986, BIOESSAYS, V4, P231
[4]  
Carr K.E., 1982, CELL STRUCTURE INTRO
[5]  
COCHRAN WG, 1957, EXPT DESIGNS, pCH7
[6]   THE INFLUENCE OF H-2-RECEPTOR ANTAGONISTS ON STEADY-STATE CONCENTRATIONS OF PROPRANOLOL AND 4-HYDROXYPROPRANOLOL [J].
DONN, KH ;
POWELL, JR ;
ROGERS, JF .
JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 24 (11-1) :500-508
[7]  
DREW R, 1981, RES COMMUN CHEM PATH, V33, P81
[9]  
Estabrook RW., 1972, METHODS PHARM, Vvol 2, P303
[10]  
FOUTS JR, 1965, J PHARMACOL EXP THER, V147, P112